Proventa’s Weekly Round-up – 10/1/19

Happy new year! It’s a fairly slow week as the sector takes stock and begins to get back, with annual price rises the main event in the news - big pharma has announced its regular price increases for the new...

7 years ago
R&D,Bioprocess,Weekly Roundups

Proventa’s Weekly Round-up – 10/1/19

Happy new year! It’s a fairly slow week as the sector takes stock and begins to get back, with annual price rises the main event in the news - big pharma has announced its regular price increases for the new...

7 years ago

The Future of Organ-on-a-Chip

Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....

7 years ago
Oncology,R&D,Biology,News

The Future of Organ-on-a-Chip

Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....

7 years ago

Proventa’s Weekly Round-up – 20/12/19

Merry Christmas! This week in our segment on “the same three stories every week that are of broad general interest”, Trump’s administration has made an attempt to reduce U.S. drug prices with a plan to allow Canadian imports; Nancy Pelosi’s...

7 years ago
Weekly Roundups

Proventa’s Weekly Round-up – 20/12/19

Merry Christmas! This week in our segment on “the same three stories every week that are of broad general interest”, Trump’s administration has made an attempt to reduce U.S. drug prices with a plan to allow Canadian imports; Nancy Pelosi’s...

7 years ago

Proventa’s Weekly Round-up – 13/12/19

Avoiding yesterday’s election and all it means for the UK and Brexit, much of the news this week happened across the pond: Pharma companies have reacted violently to the Republicans’ alleged reneging of drug patent rules in international negotiations, while...

7 years ago
Weekly Roundups

Proventa’s Weekly Round-up – 13/12/19

Avoiding yesterday’s election and all it means for the UK and Brexit, much of the news this week happened across the pond: Pharma companies have reacted violently to the Republicans’ alleged reneging of drug patent rules in international negotiations, while...

7 years ago

AI and Pharmacovigilance ADR processing

Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...

7 years ago
R&D,Pharmacovigilance,Bioinformatics

AI and Pharmacovigilance ADR processing

Many of the problems that have long been inherent in Pharmacovigilance (PV) - such as historic limitations in the information that is published in case reports, analysis of electronic health records and integration - have found an answer in the...

7 years ago

Time to invest in CGT: Its Benefits for Pharma

The concept of cell and gene therapy (CGT), wherein scientists and healthcare experts adapt cells and genes to treat illnesses, is nothing new in the life science space. Even the relatively new CRISPR has transformed into a household buzzword over...

7 years ago
Bioprocess,CGT,News

Time to invest in CGT: Its Benefits for Pharma

The concept of cell and gene therapy (CGT), wherein scientists and healthcare experts adapt cells and genes to treat illnesses, is nothing new in the life science space. Even the relatively new CRISPR has transformed into a household buzzword over...

7 years ago
Previous Page Showing 318 out of 323 Next Page
Working With us

Interested?
Reserve your space